| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T783 |
0-352 |
Sentence |
denotes |
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19: |
| T784 |
353-529 |
Sentence |
denotes |
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days, |
| T785 |
530-584 |
Sentence |
denotes |
Active comparator: control group of ordinary COVID‐19: |
| T786 |
585-683 |
Sentence |
denotes |
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization |
| T787 |
684-736 |
Sentence |
denotes |
Experimental: experimental group of severe COVID‐19: |
| T788 |
737-938 |
Sentence |
denotes |
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary: |
| T789 |
939-1031 |
Sentence |
denotes |
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021 |
